10:23 AM EST, 03/05/2024 (MT Newswires) -- Alnylam Pharmaceuticals ( ALNY ) said Tuesday that the phase 2 study of zilebesiran met the primary endpoint of "clinically and statistically significant" reductions in systolic blood pressure, or SBP, when combined with standard antihypertensive therapies.

The company said the study showed reductions in 24-hour mean SBP at month three, compared to a placebo, when added to standard treatments indapamide, amlodipine and olmesartan in three separate patient groups.

Other key endpoints include the change from baseline in average SBP over 24 hours following six months of therapy, in office systolic blood pressure at the third and sixth month, and in diastolic blood pressure gauged through both ambulatory blood pressure monitoring and office measurements at the third and sixth month, Alnylam said.

Alnylam also said that, in partnership with Roche, it has launched the global phase 2 study to evaluate zilebesiran's efficacy and safety as an add-on therapy for patients with high cardiovascular risk and uncontrolled hypertension despite standard treatments.

Price: 147.97, Change: -2.07, Percent Change: -1.38